Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
06 November 2018 - 11:00PM
Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage
biotechnology company focused on the development of first-in-class
biological therapeutics for the treatment of Duchenne muscular
dystrophy and other rare disorders, will report its third quarter
of 2018 financial results and corporate update shortly after the
NASDAQ market close on Tuesday, November 13. Management will then
host a webcast and conference call at 4:30 p.m. ET on Tuesday,
November 13.
To participate in the conference call, please dial 866-717-4562
(domestic) or 210-874-7812 (international) and reference the access
code: 4974294.
To participate via a webcast, please visit:
https://edge.media-server.com/m6/p/msqxw8py. The webcast will
be archived for approximately 30 days and will be available at
http://capricor.com/news/events/.
About Capricor Therapeutics Capricor
Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class biological therapeutics for the treatment of rare
disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic
cell therapy that is currently in clinical development for the
treatment of Duchenne muscular dystrophy. Capricor has also
established itself as one of the leading companies investigating
the field of extracellular vesicles and is exploring the potential
of CAP-2003, a cell-free, exosome-based candidate, to treat a
variety of disorders. For more information, visit
www.capricor.com.
Keep up with Capricor on social media:
www.facebook.com/capricortherapeutics,
www.instagram.com/capricortherapeutics/ and
https://twitter.com/capricor
Cautionary Note Regarding Forward-Looking
Statements
Statements in this press release regarding the
efficacy, safety, and intended utilization of Capricor's product
candidates; the initiation, conduct, size, timing and results of
discovery efforts and clinical trials; the pace of enrollment of
clinical trials; plans regarding regulatory filings, future
research and clinical trials; regulatory developments involving
products, including the ability to obtain regulatory approvals or
otherwise bring products to market; plans regarding current and
future collaborative activities and the ownership of commercial
rights; scope, duration, validity and enforceability of
intellectual property rights; future royalty streams, expectations
with respect to the expected use of proceeds from the recently
completed offerings and the anticipated effects of the offerings,
and any other statements about Capricor's management team's future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not statements of historical fact (including statements containing
the words "believes," "plans," "could," "anticipates," "expects,"
"estimates," "should," "target," "will," "would" and similar
expressions) should also be considered to be forward-looking
statements. There are a number of important factors that could
cause actual results or events to differ materially from those
indicated by such forward-looking statements. More information
about these and other risks that may impact Capricor's business is
set forth in Capricor's Annual Report on Form 10-K for the year
ended December 31, 2017 as filed with the Securities and Exchange
Commission on March 22, 2018, in its Registration Statement on Form
S-3, as filed with the Securities and Exchange Commission on
September 28, 2015, together with the prospectus included therein
and prospectus supplements thereto and in its Quarterly Report on
Form 10-Q for the quarter ended June 30, 2018, as filed with the
Securities and Exchange Commission on August 13, 2018. All
forward-looking statements in this press release are based on
information available to Capricor as of the date hereof, and
Capricor assumes no obligation to update these forward-looking
statements.
CAP-1002 is an Investigational New Drug and is
not approved for any indications. CAP-2003 has not yet been
approved for clinical investigation.
For more information, please contact:
AJ Bergmann, Chief Financial Officer
+1-310-358-3200
abergmann@capricor.com
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Apr 2024 to May 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From May 2023 to May 2024